US20120301451A1 - Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof - Google Patents

Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof Download PDF

Info

Publication number
US20120301451A1
US20120301451A1 US13/513,290 US201013513290A US2012301451A1 US 20120301451 A1 US20120301451 A1 US 20120301451A1 US 201013513290 A US201013513290 A US 201013513290A US 2012301451 A1 US2012301451 A1 US 2012301451A1
Authority
US
United States
Prior art keywords
lactobacillus
composition according
fermented composition
dsm
cereal based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/513,290
Other languages
English (en)
Inventor
Camilla Bränning
Margareta Nyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probi AB
Original Assignee
Probi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi AB filed Critical Probi AB
Assigned to PROBI AB reassignment PROBI AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NYMAN, MARGARETA, BRANNING, CAMILLA
Publication of US20120301451A1 publication Critical patent/US20120301451A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/115—Cereal fibre products, e.g. bran, husk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/20—Malt products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon, as well as to different uses of said non-fermented composition such as for the maintenance of a healthy gut-mucosa by the provision of an increased barrier function.
  • Butyric acid and glutamine have been proposed to be important for colonic health. Pure barley ⁇ -glucans have been shown to give comparatively high amounts of butyric acid, and germinated barley foodstuff, obtained from brewer's spent grain (BSG), containing high amounts of ⁇ -glucans and glutamine, has been reported to reduce the inflammatory response in the colon of subjects with ulcerative colitis.
  • BSG spent grain
  • Dietary fiber is resistant to digestion in the small intestine and is therefore available for fermentation by the microbial flora in the large intestine, forming short-chain fatty acids (SCFA) together with gases and heat.
  • SCFA short-chain fatty acids
  • the principal SCFA formed are acetic, propionic and butyric acids, while valeric, caproic, heptanoic acids and the branched iso-butyric and iso-valeric acids are formed in lesser amounts.
  • the SCFA are absorbed and transported via the portal vein to the liver, and the fraction not absorbed is excreted in feces.
  • Propionic acid is a substrate for hepatic gluconeogenesis and has been reported to inhibit cholesterol synthesis, while acetic acid has been shown to stimulate the gluconeogenesis and the formation of cholesterol via acetyl-CoA.
  • Butyric acid is the major energy source for colonocytes, and has been hypothesized to reduce the risk of colon cancer and to benefit IBD. Recently, butyric acid has also been suggested to have metabolic effects.
  • glutamine is one amino acid of special interest.
  • Glutamine together with butyric acid, is an important substrate for the colon epithelial cells. This is of interest since the presence of high amounts of butyric acid in colon will reduce the epithelial cells' need for glutamine, and in this way increase the glutamine levels in the blood. High levels of glutamine in the circulating system have been found to be positive since it improves the immune defense.
  • Cereal-based foods have been used for a very long time, and the cereal grains contain the protein, fat and carbohydrate required by humans for growth and maintenance. Fermentation of barley may produce high amounts of butyric acid, due to its high content of ⁇ -glucans, and it has been shown that germinated barley foodstuff (GBF) contains high amounts of glutamine. Glutamine in GBF has been reported to be bound to the dietary fiber and reach the large intestine, where it can be liberated during fermentation and be a substrate for the colonic mucosa. In studies where GBF has been used, the symptoms and inflammations were ameliorated in rats induced with dextran sulfate sodium (DSS) colitis. The same effect was seen in humans with ulcerative colitis.
  • DSS dextran sulfate sodium
  • Probiotic bacteria are defined as live microorganisms which when administered in adequate amounts beneficially affect the host. Lactobacilli and bifidobacteria are the most frequently used bacteria in probiotic products. These bacteria are generally safe, as are probiotics based on these organisms. The lack of pathogenicity extends across all age groups and to immunocompromised individuals. Intake of different probiotic bacteria has been shown to have clinical benefits in various physiologic or pathologic situations. The most clear cut effects have been shown in diarrhea caused by antibiotic therapy or rotavirus infection. There are also studies showing positive clinical effects in inflammatory bowel diseases, atopic dermatitis and hypercholesterolemia after intake of probiotic bacteria. The mechanism, by which probiotic bacteria contribute to these clinical improvements are not clear.
  • Lactobacillus rhamnosus is one of the largest bacterial groups represented in the bowel of healthy individuals. High amounts of probiotic bacteria may obstruct the proliferation of pathogenic bacteria. A combination of pre- and probiotics may not only affect the microbiota but also optimize the formation of CA.
  • WO2007036230 discloses a ready-to-use product comprising fermented cereal and non-pathogenic microorganisms, wherein the fermented cereal is preferably oatmeal.
  • the present invention differs from WO2007036230 by the fact that the present compositions are non-fermented and
  • the aim of the present invention is to investigate the potential role of a few cereal based fractions, such as different barley fractions, as a prebiotic product, regarding the cecal formation of CA, levels of SCFA and amino acids in blood, and the cecal composition of the bacterial flora (lactobacilli, bifidobacteria, Enterobacteriacece), and whether the addition of a probiotic strain would give any further effects.
  • the present invention relates, in one aspect, to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus.
  • the present invention relates, in a further aspect, to the use of said non-fermented composition as a synbiotic.
  • the present invention relates, in a yet further aspect, to said non-fermented composition, for use in treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD).
  • IBS Irritable bowel syndrome
  • IBD Inflammatory bowel disease
  • the present invention relates, in a yet further aspect, to said non-fermented composition, for use in the maintenance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gut-mucosa.
  • FIG. 1 shows the bacterial counts of Lactobacillus (white bars), Bifidobacterium (black bars) and Enterobacteriaceae (checked bars) in cecum content of rats fed whole grain barley (WGB), malt (Malt) or brewer's spent grain (BSG), and the same diets supplemented with L. rhamnosus (Lr).
  • Values are means and those values of WGB, Malt and BSG, i.e. those without any added probiotics, with dissimilar superscript letters were significantly different, P ⁇ 0.05. Mean values were significantly different from those for rats fed diets without bacteria, *P ⁇ 0.05
  • the present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus .
  • the meaning of the phrase “having the ability to increase the formation of butyric acid in the colon” means that the present non-fermented composition comprising both a probiotic and a cereal based fraction will increase the formation of butyric acid in the colon and in blood, see table 4 and 5, compared to when a cereal based fraction is given only without a probiotic.
  • butyric acid in the colon has increased 157% (from 7 to 18 ⁇ mol/g) for whole grain barley, 50% (from 12 to 18 ⁇ mol/g) for malted barley and 33% (from 9 to 12 ⁇ mol/g) for Brewers spent grain.
  • an increase of the formation of butyric acid is in the range of 30-200%, preferably in the range of 40-180%, more preferably in the range of 50-160%.
  • the butyric acid content formed in the colon is in the range of 14-20 ⁇ mol/g or >14 ⁇ mol/g.
  • non-fermented composition should be interpreted as the not yet consumed composition. It is intended that the fermentation should occur in the gastrointestinal tract after consuming the composition.
  • the organic acids formed during gastrointestinal fermentation are measured in blood and cecal contents.
  • dried products of the invention such as cereals, muesli, breads, biscuits, cereals, health bars, or spreads the organic acids are not present in the composition due to non-fermentation.
  • the bacteria could be present in an encapsulated form preventing them from fermenting the composition before entering the gastrointestinal tract.
  • Another approach for preventing fermentation is keeping the composition at a low temperature, i.e. keeping the composition refrigerated or frozen at appropriate temperatures and shelf life.
  • the non-fermented compositions of the invention may be a dried composition and fluid composition.
  • the cereal based fraction is present in the non-fermented composition in the range of 40-100% weight.
  • the remaining contents of the composition are apparent to a person skilled in the art of formulating synbiotic compositions.
  • the at least one cereal based fraction of the composition is a whole grain cereal fraction such as a whole grain barley, a whole grain oat, a whole grain wheat, a whole grain rye or a combination thereof.
  • the at least one cereal based fraction used in the composition of the invention may have been processed in different ways before being added to the present composition, for instance the cereal based fraction could be a milled and/or heat treated cereal based fraction, or an extruded, expanded cereal based fraction, or a drum-dried cereal based fraction, or a flaked cereal based fraction or a steam-cooked cereal based fraction.
  • the at least one cereal based fraction is chosen from the group of a barley fraction, an oat fraction, a wheat fraction, a rye fraction and any combination thereof.
  • the at least one cereal based fraction may additionally be malted and in one embodiment of the invention the malted cereal based fraction is malt or brewer's spent grain (BSG), which is a by-product of the brewing process.
  • BSG brewer's spent grain
  • BSG is the by-product when the mixture is filtrated and the filtrate continues to the next brewing processing step. BSG has often been used as cattle feed, but results from earlier studies indicate that it is of interest to examine whether BSG may be used as prebiotics in human food.
  • the cereal based fraction has been milled in order to have a suitable size in the composition, wherein the size of the at least one cereal based fraction is in the range of approximately 0.1 mm-10 mm, preferably 0.5 mm to 5 mm.
  • the at least one isolated strain of Lactobacillus is present in an amount of 10 6 -10 14 CFU/day, preferably 10 8 -10 12 CFU/day, more preferably 10 9 -10 11 CFU/day.
  • CFU stands for colony forming units and is a well known unit for a person skilled in the art of probiotics.
  • the at least one isolated probiotic strain is chosen from the group of Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus rhamnosus, Lactobacillus paracasei and Lactobacillus fermentum.
  • the at least one isolated probiotic strain is a Lactobacillus rhamnosus 271 (DSM 6594).
  • the at least one probiotic strain is chosen from the group of Lactobacillus plantarum 299, DSM 6595 , Lactobacillus plantarum 299v, DSM 9843 , Lactobacillus plantarum HEAL 9, DSM 15312 , Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316.
  • Lactobacillus plantarum 299, DSM 6595, and Lactobacillus rhamnosus 271 were deposited on 2 Jul. 1991 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Lactobacillus plantarum 299v, DSM 9843, was deposited on 16 Mar. 1995 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Lactobacillus plantarum HEAL 9, DSM 15312 , Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316, were deposited on Nov. 27, 2002, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
  • the at least one probiotic may be present in the composition as a freeze-dried component, in the form of a probiotic in an oil, in the form of a probiotic in a aqueous solution or suspension, in the form of spray-dried probiotic, or in the form of probiotic in a hard fat state.
  • said composition is a liquid formulation or a solid formulation.
  • conventional additives as used in the technical field will be used and are realized by a person skilled in the technical field.
  • said composition is a medical food, a functional food, a dietary supplement, a nutritional product, a food or a food additive.
  • the food additive could for instance be added to cereals, muesli, breads, biscuits, cereals, health bars, or spreads as a mixed powder composition or each component separately.
  • An example of the latter is for instance the spreading of the cereal based fraction onto the relevant food such as muesli and thereafter adding the relevant probiotic strain.
  • the beneficial effects of the invention are obtained when the cereal based fraction and the probiotic strains are taken together. It should be understood that it is not necessary the combination is given as a composition. It is for instance possible to mix the components precisely before intake.
  • the food is a drink, a beverage, a yoghurt, a juice or an ice cream.
  • the composition could be easily taken in the form of a food on a daily basis.
  • the general health of mankind could become better by the use of the composition according to the invention.
  • composition of the present invention may be used as a synbiotic.
  • a synbiotic is a supplement that contains both a prebiotic and a probiotic that work together to improve the “friendly flora” of the human intestine.
  • the invention relates to the use of a composition, for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD).
  • a composition for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD).
  • the invention relates to a composition as defined herein for use in the maintenance of a healthy gut-mucosa and/or in the provision of an increased barrier function of the gut-mucosa.
  • the raw material used was whole grain barley (Viking Malt AB, Halmstad, Sweden), malt and brewer's spent grain (Carlsberg, Falkenberg, Sweden).
  • Whole grain barley, malt and brewer's spent grain came from the same batch of flour.
  • the raw materials were milled before being included in the diets to a particle size in the range of about 1 mm.
  • the bacterial strain included in the experiment was L. rhamnosus 271 (Probi AB, Lund Sweden) and it was delivered freeze-dried.
  • test diets were prepared according to Table 1: one reference diet containing whole grain barley (WGB), and 5 test diets including whole grain barley and L. rhamnosus 271 (WGB+Lr), malt (Malt), malt and L. rhamnosus 271 (Malt-FLr), brewer's spent grain (BSG) or brewer's spent grain and L. rhamnosus 271 (BSG-FLr).
  • the raw materials were added at a level of 80 g dietary fiber/kg diet (dwb, dry weight basis). Wheat starch was used to adjust the dry matter content, and this type of starch has previously been shown to be completely digested, and therefore does not form any CA.
  • the probiotic strain was included daily in the diet at feeding time for each rat in the amount of 2 ⁇ 10 8 colony forming units (CFU)/d.
  • Table 1 shows the composition of the test diets given to rats in the following groups: whole grain barley (WGB), malt (Malt) or brewer's spent grain (BSG) with or without the addition of L. rhamnosus (Lr) (Table 1).
  • mice Male Wistar rats (initial weight, 134 ⁇ 1 g) were obtained from Scanbur (Sollentuna, Sweden). They were randomly divided into six groups, seven rats in each, and housed individually in metabolic cages, in a room maintained at 22° C., with 12-hour light/dark cycles. The feed intake was restricted to 12 g/d (dwb) and the rats were given free access to water. The animals were allowed to adapt to the diet for 7 d and then followed a 5-d long experimental period when feces and feed residues were collected daily. The fecal samples were stored at ⁇ 20° C. and then freeze-dried and milled before analysis of dietary fiber.
  • the animals were anaesthetized by subcutaneous injection of a mixture (1:1:2) of Hypnorm (Division of Janssen-Cilag Ltd., Janssen Pharmaceutica, Beerse, Belgium), Dormicum (F. Hoffman-La Roche AG, Basel, Switzerland) and sterile water at a dose of 0.15 ml/100 g and blood, cecal tissue and content were collected.
  • the blood samples were drawn from the portal vein and sampled into two tubes: one for plasma containing EDTA and one for serum.
  • the plasma and serum samples were centrifuged for 15 min (2500 ⁇ g) and then stored at ⁇ 40° C. until analysis of amino acids and SCFA. Cecal tissue weight, content and pH were measured directly.
  • the cecal content was divided into one sterile tube containing freezing media and immediately frozen in liquid nitrogen for analysis of the microbiota and the other part of the cecal content was frozen and stored at ⁇ 40° C. until analysis of the CA, which was also done for the different parts of the hindgut.
  • a gravimetrical method was used to determine the amount of soluble and insoluble dietary fiber in the raw materials.
  • the composition of the isolated fiber residue was analyzed using gas-liquid chromatography (GLC) of the neutral sugars as their alditol acetates, and the content of uronic acids was analyzed with a spectrophotometric method.
  • the fiber monomers in feces were characterized directly without prior isolation of dietary fiber.
  • a GLC method was used to analyze the SCFA (acetic, propionic, isobutyric, butyric, isovaleric, valeric, caproic, and heptanoic acids) in the intestinal content (cecum, proximal and distal colon).
  • Dilution solution 2.5 M HCl
  • 2-ethylbutyric acid internal standard, 1 mM
  • Succinic and lactic acid were quantified spectrophotometrically with commercially available enzymatic kits (Cat. Nos. 10176281035 and 1112821, respectively; Boehringer Mannheim, Mannheim, Germany). The procedures were performed according to the manufacturer's instructions.
  • the SOFA in serum were analyzed with a GLC method.
  • Water and 2-ethylbutyric acid (internal standard, 1 mM) together with hydrochloric acid were added to the samples, and then a hollow fiber was immersed in the serum solution to extract the SOFA.
  • the SOFA were flushed from the fiber lumen and then injected onto a fused-silica capillary column (DB-FFAP 125-3237, J&W Scientific, Agilent Technologies Inc., Folsom, Calif. USA).
  • GC ChemStation software (Agilent Technologies Inc., Wilmington, Del., USA) was used for the analysis.
  • Sulfosalicylic acid was added to the plasma samples to purify free amino acids by precipitating high-molecular-weight proteins.
  • An amino acid analyzer Biochrom 30, Biochrom Ltd, Cambridge, England
  • ion-exchange chromatography was used to quantify the amount of amino acids.
  • the EZChrom Elite software package (Scientific Software Inc., Pleasanton, Calif., USA) was used for the analysis.
  • the dietary fiber content was similar in whole grain barley and malt (15.4 and 12.1 g/100 g, dwb, respectively), while brewer's spent grain contained 4-5 times more dietary fiber (58.2 g/100 g, dwb).
  • the main components of the dietary fiber polysaccharides were glucose (35-49%), xylose (29-35%) and arabinose (16-22%). Dietary fiber polysaccharides in whole grain barley and brewer's spent grain were more fermented in the rat colon than malt (Table 2).
  • the probiotic strain affected the cecal levels of more individual CA than the different fiber fractions.
  • individual significant differences between diets containing L. rhamnosus and their corresponding diets without this probiotic strain were only seen in rats fed WGB.
  • the major acid formed in cecum of rats fed the six test diets was acetic acid (62 ⁇ 3%), followed by butyric acid (15 ⁇ 4%) and propionic acid (14 ⁇ 1%).
  • Malt + Lr, n 6.
  • 2 Mean values of WGB, Malt and BSG, i.e. those without any added probiotics, with dissimilar superscript letters were significantly different (P ⁇ 0.05).
  • Acetic acid (976-1596 ⁇ mol/l), propionic acid (72-195 ⁇ mol/l) and butyric acid (46-208 ⁇ mol/l) were the major acids in the portal blood (Table 5).
  • the total amounts of amino acids were approximately the same in whole grain barley and malt (9.7 g/100 g and 9.5 g/100 g), whereas brewer's spent grain contained considerably more (24.3 g/100 g) (Table 6).
  • the amino acid pattern of the barley products was similar to the highest proportion of glutamic acid, followed by proline, leucine and asparagine acid.
  • Butyric acid has been proposed to be important for colonic health, e.g. by reducing the risk of inflammatory bowel diseases and colon cancer. These effects may be due to its function as the main energy source of the epithelial cells, and its major role in regulation of cell proliferation and differentiation.
  • Glutamine has been reported to also be a major energy source of mucosal epithelial cells, and as such able to recover and preserve the intestinal mucosa and prevent bacterial translocation.
  • GBF known to contain high amounts of ⁇ -glucans and glutamine, has been reported to reduce the epithelial inflammatory response both in subjects with ulcerative colitis and in mice with DSS-induced colitis.
  • rhamnosus were used to evaluate the potential role of brewer's spent grain (BSG) as a prebiotic product, regarding the cecal formation of CA, levels of SCFA and amino acids in blood, and the cecal composition of the bacterial flora (lactobacilli, bifidobacteria, Enterobacteriacece) in rats compared with grain barley (WGB) and malt (Malt), and whether the supplementation of L. rhamnosus gave any additional effects.
  • BSG spent grain
  • Rats fed Malt had the highest butyric acid level in the distal part of the colon (P ⁇ 0.05 compared with WBG). It is of great importance that dietary fibers are able to reach not only the proximal colon but also the distal part, because colonic diseases such as ulcerative colitis and colonic cancer usually occur in this site of the colon. Subjects with ulcerative colitis increased their fecal levels of butyric acid after 4 weeks on a diet with R-glucan enriched oat bran, and unlike controls, complaints at entry were improved with this treatment. Similar results were obtained by Kanauchi and collaborators with germinated barley foodstuff.
  • the number of bifidobacteria counts was lower with Malt than with the other barley fractions. Although the bacteria counted in this experiment does not make up for the whole microbiota, it may indicate that the microbiota was altered. A changed microbiota may also result in other pathways for fermentation and a changed formation of degradation products, as judged by the higher levels of butyric acid in the cecum and the distal part of colon in rats fed Malt compared with the other barley products.
  • butyric acid may reduce the need for glutamine, thereby increasing the circulating glutamine levels.
  • Malt giving high amounts of butyric acid did not show on any higher levels of glutamine in plasma of rats than the other barley fractions, indicating that glutamine does not reach the colon to any great extent and therefore is not absorbed there.
  • blueberry husks in a diet containing casein as protein source have been shown to give similar plasma levels of glutamine as in this experiment, using the same animal model (data not published). This may imply that none of the barley fractions used in this experiment increased plasma levels of glutamine more than casein.
  • the beneficial effects of GFB in man with ulcerative colitis and in rats with DSS-induced colitis have partly been ascribed to glutamine.
  • glutamine is converted into glutamic acid, and the amount of glutamic acid therefore also includes the amount of glutamine.
  • glutamine in barley has been reported to be bound to the dietary fiber, reaching the colon and after fiber fermentation being a substrate for the colonic mucosa.
  • glutamine is known to be very fragile amino acid, and most of the glutamine not bound to the dietary fiber is degraded by gastric acid. The Malt group had lower plasma levels of glutamine, and it might be speculated whether this was connected to the malting process in some way. As discussed above, it seems as if the dietary fiber was degraded during malting, which may result in less amounts of bound glutamine.
  • the ammonia plasma level in the Malt group was higher than in rats fed WGB and BSG.
  • the origin of ammonia in the portal vein is complex, but some arises from the metabolism of glutamine. This may be another reason for the lower proportion of glutamine in the Malt group.
  • Previous studies in man have shown that an increased number of fecal bifidobacteria was associated with a reduced level of ammonia in feces and blood.
  • Bifidobacterium spp. are known to use the ammonia as a nitrogen source for their growth.
  • Rats fed Malt had a lower viable count of cecal bifidobacteria, indicating that this could explain the higher proportion of ammonia, found in the portal blood.
  • Ammonia has been shown to be toxic to cells, and to alter synthesis of DNA, and thus has been proposed to be a promoter of carcinogenesis in humans.
  • One way of decreasing the level of ammonia in rats fed Malt may be to add bifidobacteria.
  • the L. rhamnosus used in this experiment did not decrease, but rather increased the level of ammonia in blood.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
US13/513,290 2009-12-22 2010-12-22 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof Abandoned US20120301451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0951011 2009-12-22
SE0951011-6 2009-12-22
PCT/SE2010/051464 WO2011078781A1 (en) 2009-12-22 2010-12-22 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2010/051464 A-371-Of-International WO2011078781A1 (en) 2009-12-22 2010-12-22 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/282,059 Division US11318181B2 (en) 2009-12-22 2019-02-21 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof

Publications (1)

Publication Number Publication Date
US20120301451A1 true US20120301451A1 (en) 2012-11-29

Family

ID=44196038

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/513,290 Abandoned US20120301451A1 (en) 2009-12-22 2010-12-22 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
US16/282,059 Active 2031-08-31 US11318181B2 (en) 2009-12-22 2019-02-21 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/282,059 Active 2031-08-31 US11318181B2 (en) 2009-12-22 2019-02-21 Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof

Country Status (15)

Country Link
US (2) US20120301451A1 (ja)
EP (1) EP2515937B1 (ja)
JP (1) JP5932662B2 (ja)
KR (1) KR101857617B1 (ja)
CN (1) CN102770155B (ja)
AU (1) AU2010334993B2 (ja)
BR (1) BR112012015033B1 (ja)
CA (1) CA2784723C (ja)
ES (1) ES2766300T3 (ja)
MX (1) MX348112B (ja)
NZ (1) NZ600258A (ja)
PL (1) PL2515937T3 (ja)
RU (1) RU2580040C2 (ja)
WO (1) WO2011078781A1 (ja)
ZA (1) ZA201203941B (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008392A1 (en) * 2013-03-01 2016-01-14 Hayashibara Co., Ltd. Agent for lifestyle-related disease and oral composition comprising same
IT201900010110A1 (it) * 2019-06-26 2020-12-26 Roberto Battoia Alimento funzionale
US11400124B2 (en) 2016-05-13 2022-08-02 Sofar S.P.A. Use of probiotics for improving protein absorption
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
KR20230121689A (ko) * 2020-08-25 2023-08-21 단국대학교 천안캠퍼스 산학협력단 천년초 추출물 및 유산균을 포함하는 과민성장증후군개선용 신바이오틱스 조성물
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US11839634B2 (en) 2013-09-06 2023-12-12 Alfasigma S.P.A. Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3329927B1 (en) * 2011-11-16 2023-09-27 Multigerm UK Enterprises Ltd. Ibs treatment with probiotics
CN104781390B (zh) * 2012-08-16 2017-07-28 庆熙大学校产学协力团 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌
CN102919669B (zh) * 2012-10-12 2014-11-05 上海致一食品有限公司 以谷物粉为包埋材料制作固定化益生菌的方法
GB201501938D0 (en) * 2015-02-05 2015-03-25 Multigerm Uk Entpr Ltd Probiotic preparation
CN107920575A (zh) * 2015-07-01 2018-04-17 裕得生物科技有限公司 一种合生素发酵产物的制造方法及由此制造的合生素发酵产物
WO2017026620A1 (ko) * 2015-08-13 2017-02-16 한국식품연구원 락토바실러스 펜토서스를 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환, Ｔｈ17-매개 면역 질환, 또는 Ｔｈ2-매개 면역 질환의 예방, 개선, 또는 치료용 조성물
TWI564389B (zh) * 2015-12-07 2017-01-01 New Bellus Enterprises Co Ltd 新穎乳酸菌、含有該乳酸菌之組合物及其用途
CN108013473B (zh) * 2017-11-20 2021-06-18 陕西海升果业发展股份有限公司 一种益生菌冻干块及制备方法以及基于该冻干块的即食水果谷物麦片及制备方法
WO2019119261A1 (en) * 2017-12-19 2019-06-27 Dupont Nutrition Biosciences Aps Probiotics for cognitive and mental health
CA3103831A1 (en) * 2018-06-15 2019-12-19 University Of Tasmania Preparation for the treatment of inflammatory bowel disease using a whole plant fibre extract from sugarcane
GB201908154D0 (en) * 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
KR102461810B1 (ko) * 2020-04-23 2022-11-04 대한민국 새싹보리 추출물의 장내균총 개선에 따른 장건강 개선용 조성물
CN114262678B (zh) * 2021-12-28 2023-05-26 杭州普元生物技术有限公司 一种发酵乳杆菌Pm007及其应用
WO2024068304A1 (en) 2022-09-30 2024-04-04 Evonik Operations Gmbh Probiotic strains for the treatment of irritable bowel syndrome and fodmap intolerance

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260092A (en) * 1978-04-24 1993-11-09 F.I.N.D. Research Corporation Husk-free protein from spent grains of barley
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US6348221B1 (en) * 1996-04-05 2002-02-19 Kirin Beer Kabushiki Kaisha Substance originating in germinating seeds of gramineous plant and containing proteins and insoluble dietary fibers and use thereof
US20070231311A1 (en) * 2006-04-03 2007-10-04 Kroening Kurt D Method for preserving grain by-products
US20080193485A1 (en) * 2005-02-15 2008-08-14 Gorbach Sherwood L Food Containing a Probiotic and an Isolated Beta-Glucan and Methods of Use Thereof
US20080311097A1 (en) * 2005-09-28 2008-12-18 Nordisk Rebalance A/S Treatment of Ibd and Ibs Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors
US20110262571A1 (en) * 2008-12-17 2011-10-27 Kirin Holdings Kabushiki Kaisha Irritable bowel syndrome inhibiting substance containing insoluble dietary fiber from seed of grain plant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0659169B2 (ja) * 1988-02-10 1994-08-10 森永乳業株式会社 飼料用ビール粕発酵物の製造法
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
US6241983B1 (en) * 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
KR20000064729A (ko) * 1996-03-20 2000-11-06 번스 필프 앤드 컴파니 리미티드 위장관에서의미생물개체군의변경
AUPO430496A0 (en) * 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
JP2002119276A (ja) * 2000-10-13 2002-04-23 T-Cell Biotechnology Food Co Ltd ラクトバチルス・ラムノーサス株及びその使用
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
DE10105347A1 (de) * 2001-02-05 2002-08-22 Nutrinova Gmbh Sorbinsäurepräparat enthaltend Probiotika als Futtermittelzusatz in der Nutztieraufzucht
CN100402042C (zh) * 2002-03-13 2008-07-16 基博生物技术公司 增强肾功能的组合物及方法
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
SE527555C2 (sv) 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
JP5095912B2 (ja) 2004-09-06 2012-12-12 雪印メグミルク株式会社 免疫増強剤
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
RU2284703C1 (ru) * 2005-03-21 2006-10-10 Всероссийский государственный научно-исследовательский институт животноводства (ВИЖ) Способ кормления поросят
EP1769801A1 (en) * 2005-09-28 2007-04-04 Hans Israelsen Use of a fermented cereal composition for the treatment of IBD and IBS
US20090130249A1 (en) * 2007-11-20 2009-05-21 Cargill, Incorporated Methods to deliver low-inclusion ingredients into an animal feed ration

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260092A (en) * 1978-04-24 1993-11-09 F.I.N.D. Research Corporation Husk-free protein from spent grains of barley
US6348221B1 (en) * 1996-04-05 2002-02-19 Kirin Beer Kabushiki Kaisha Substance originating in germinating seeds of gramineous plant and containing proteins and insoluble dietary fibers and use thereof
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US20080193485A1 (en) * 2005-02-15 2008-08-14 Gorbach Sherwood L Food Containing a Probiotic and an Isolated Beta-Glucan and Methods of Use Thereof
US20080311097A1 (en) * 2005-09-28 2008-12-18 Nordisk Rebalance A/S Treatment of Ibd and Ibs Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors
US20070231311A1 (en) * 2006-04-03 2007-10-04 Kroening Kurt D Method for preserving grain by-products
US20110262571A1 (en) * 2008-12-17 2011-10-27 Kirin Holdings Kabushiki Kaisha Irritable bowel syndrome inhibiting substance containing insoluble dietary fiber from seed of grain plant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Derwent, 2007, Derwent Abstract for RU 2254703, Accession No. 2007-069807, Abstract only cited, pp. 1-2 *
Mussatto et al., 2006, Journal of Cereal Science, 43, 1-14 *
Please amend the PTO-892 mailed 17 Sept. 2013 as follows: Delete "Derwent, 2007, Derwent Abstract for RU 2254703, Accession No. 2007-069807, Abstract only cited, pp. 1-2" and replace with "Derwent, 2007, Derwent Abstract for RU 2284703, Accession No. 2007-069807, Abstract only cited, pp. 1-2" (Reference provided with action of 17 Sept. 2013.) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008392A1 (en) * 2013-03-01 2016-01-14 Hayashibara Co., Ltd. Agent for lifestyle-related disease and oral composition comprising same
US11839634B2 (en) 2013-09-06 2023-12-12 Alfasigma S.P.A. Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11400124B2 (en) 2016-05-13 2022-08-02 Sofar S.P.A. Use of probiotics for improving protein absorption
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease
IT201900010110A1 (it) * 2019-06-26 2020-12-26 Roberto Battoia Alimento funzionale
WO2020261132A1 (en) * 2019-06-26 2020-12-30 Battoia Roberto Functional food
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
KR20230121689A (ko) * 2020-08-25 2023-08-21 단국대학교 천안캠퍼스 산학협력단 천년초 추출물 및 유산균을 포함하는 과민성장증후군개선용 신바이오틱스 조성물
KR102670126B1 (ko) * 2020-08-25 2024-05-29 단국대학교 천안캠퍼스 산학협력단 천년초 추출물 및 유산균을 포함하는 과민성장증후군 개선용 신바이오틱스 조성물

Also Published As

Publication number Publication date
WO2011078781A1 (en) 2011-06-30
MX2012007240A (es) 2012-10-15
US20190201473A1 (en) 2019-07-04
AU2010334993B2 (en) 2015-07-09
CA2784723C (en) 2021-01-12
EP2515937A4 (en) 2015-04-29
PL2515937T3 (pl) 2020-05-18
ES2766300T3 (es) 2020-06-12
US11318181B2 (en) 2022-05-03
CA2784723A1 (en) 2011-06-30
KR20120107106A (ko) 2012-09-28
ZA201203941B (en) 2013-08-28
AU2010334993A1 (en) 2012-06-21
MX348112B (es) 2017-05-26
JP5932662B2 (ja) 2016-06-08
JP2013515051A (ja) 2013-05-02
KR101857617B1 (ko) 2018-05-15
RU2580040C2 (ru) 2016-04-10
EP2515937A1 (en) 2012-10-31
BR112012015033B1 (pt) 2020-11-03
BR112012015033A2 (pt) 2017-12-12
EP2515937B1 (en) 2019-10-23
NZ600258A (en) 2014-01-31
RU2012125192A (ru) 2014-01-27
CN102770155A (zh) 2012-11-07
CN102770155B (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
US11318181B2 (en) Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
RU2376889C2 (ru) Пищевой продукт и напиток, модулирующий кишечную флору человека, пищевые добавки, способы их получения и применения препаратов арабиноксилана
CA2746008C (en) Nutriment containing arabinoxylan and oligosaccharides
JP7280243B2 (ja) 栄養組成物並びに該栄養組成物を用いた飲食品組成物及び調製粉乳
US20100074878A1 (en) Probiotic bacterium: lactobacillus fermentum
US20110052538A1 (en) Probiotic/non-probiotic combinations
Bränning et al. Malt in combination with Lactobacillus rhamnosus increases concentrations of butyric acid in the distal colon and serum in rats compared with other barley products but decreases viable counts of cecal bifidobacteria
WO2021149663A1 (ja) 組成物
US20150313952A1 (en) Synbiotic composition and use thereof
JP5130593B2 (ja) 爆砕発酵処理食物繊維含有組成物
Bränning et al. Blueberry husks and multi-strain probiotics affect colonic fermentation in rats
CN115915965B (zh) 降低谷物中植酸的方法
JP7368484B2 (ja) 組成物並びに該組成物含有する飲食品組成物および調製乳
AU2015202992A1 (en) Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
Salovaara et al. Fermented cereal-based functional foods
JP7309436B2 (ja) 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
US20140079833A1 (en) Food product comprising rye
Hernandez et al. Development of probiotics and prebiotics
KR20220037662A (ko) 노을찰 수수를 포함하는 장 기능 개선용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROBI AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRANNING, CAMILLA;NYMAN, MARGARETA;SIGNING DATES FROM 20120614 TO 20120621;REEL/FRAME:028780/0124

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION